No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
OCGN240517P1500
- 0.05
- -0.05-50.00%
15min DelayClose May 14 15:49 ET
0.10High0.03Low
0.05Open0.10Pre Close350 Volume5.54K Open Interest1.50Strike Price1.87KTurnover212.42%IV-14.71%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.05Time Value100Contract SizeAmericanOptions Type-0.2313Delta0.9073Gamma34.00Leverage Ratio-0.0170Theta0.0000Rho-7.86Eff Leverage0.0005Vega
Intraday
- 5D
- 1D
News
Ocugen Q1 2024 GAAP EPS $(0.05) Beats $(0.06) Estimate, Sales $1.014M Up From $443.000K YoY
Ocugen Q1 2024 GAAP EPS $(0.05) Beats $(0.06) Estimate, Sales $1.014M Up From $443.000K YoY
Earnings Call Summary | Ocugen(OCGN.US) Q1 2024 Earnings Conference
The following is a summary of the Ocugen, Inc. (OCGN) Q1 2024 Earnings Call Transcript:Financial Performance:Ocugen's R&D expenses for Q1 2024 were $6.8 million, a decrease compared to $10.2 million i
Ocugen, Inc. (OCGN) Q1 2024 Earnings Call Transcript
Ocugen, Inc. (OCGN) Q1 2024 Earnings Call Transcript
Express News | Ocugen Inc Qtrly Shr Loss $0.05
Express News | Ocugen Inc: Ocu400 on Track to Meet 2026 Biologics License Application (Bla) and Market Authorization Application (Maa) Approval Targets
Express News | Ocugen Q1 Net Income USD -11.924 Million
Comments
$Ocugen(OCGN.US$ this stock is good to hold long, love it 🩵
2
1
$Ocugen(OCGN.US$ Ocugen Q1 2024 GAAP EPS $(0.05) Beats $(0.06) Estimate, Sales $1.014M Up From $443.000K YoY
5
$Ocugen(OCGN.US$ stay tune, 8.30am ET quarter earning release 🚀🚀
2
$Ocugen(OCGN.US$ Well this keep going tomorrow?
4
Read more
Trytosaveabit : Yes it’s a longer hold! Nice pipeline but kinda far out there! But I like it as well! GL